Human trial42 patientsCohort study

Metabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin

Figure 1. Clinical study design.
Open the figure at full size
Figure 1. Clinical study design.Clinical study design.Habeos et al. · CC BY

Biomedicines

Abstract

Background/Objectives: This study evaluated the metabolic effects of empagliflozin, an SGLT2 inhibitor (SGLT2i), in type 2 diabetes patients. Methods: In an observational cohort study, 42 patients received empagliflozin for 1 month, with serum and urine analyzed for IL-6, NT-proBNP, iron metabolism markers, and electrolytes.

The paper

University of Patras

Biomedicines · 8 Sep 2026 · CC BY

doi.org/10.3390/biomedicines14092016PubMed 42792758

More on Inflammation